Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms
- 1 June 2005
- journal article
- research article
- Published by Elsevier in Schizophrenia Research
- Vol. 75 (1) , 21-26
- https://doi.org/10.1016/j.schres.2004.12.011
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Pharmacogenomics in schizophrenia: the quest for individualized therapyHuman Molecular Genetics, 2002
- Association of CYP 3 A 4 genotype with treatment-related leukemiaProceedings of the National Academy of Sciences, 1998
- Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.Psychopharmacology, 1997
- Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotypeThe British Journal of Psychiatry, 1997
- Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1995
- Genetically variable metabolism of antidepressants and neuroleptic drugs in manPharmacogenetics, 1993
- Predictors of the course of tardive dyskinesia in patients receiving neurolepticsBiological Psychiatry, 1992
- A permanent dopamine receptor up-regulation in the ovariectomized ratPharmacology Biochemistry and Behavior, 1989
- Sulpiride in Tardive DyskinesiaActa Psychiatrica Scandinavica, 1984
- Levodopa and receptor sensitivity modification in tardive dyskinesiaPsychopharmacology, 1982